[68Ga]Ga-成纤维细胞活化蛋白抑制剂-04与[18F]FDG PET显像在孤立性纤维性肿瘤中的比较及FAP靶向放射性药物治疗的初步应用
研究纳入31例疑似复发或转移性孤立性纤维性肿瘤患者,同期行[18F]FDG与[68Ga]Ga-FAPI-04 PET/CT,比较病灶检出率与SUVmax;4例高摄取患者接受单周期2.22 GBq [177Lu]Lu-Evans blue-FAPI治疗并随访4个月。[68Ga]Ga-FAPI-04检出病灶比例87.0%高于[18F]FDG的45.4%(P<0.001),多数器官SUVmax更高,4例患者耐受良好且病情稳定。
要点
- [68Ga]Ga-FAPI-04 PET检出病灶比例87.0%,高于[18F]FDG的45.4%(P<0.001)。
- 多数复发或转移器官中[68Ga]Ga-FAPI-04的SUVmax高于[18F]FDG。
- 4例高摄取患者接受单周期2.22 GBq [177Lu]Lu-Evans blue-FAPI治疗,耐受良好且随访病情稳定。
关键数值与推荐
- [68Ga]Ga-FAPI-04 PET检出病灶比例87.0%,[18F]FDG为45.4%(P<0.001)。
- 骨、肺、中枢神经系统、胰腺和胸膜中[68Ga]Ga-FAPI-04的SUVmax高于[18F]FDG(P<0.001)。
- 肾和腹盆腔中[68Ga]Ga-FAPI-04的SUVmax高于[18F]FDG(P=0.001)。
- 肌肉和心包中[68Ga]Ga-FAPI-04的SUVmax高于[18F]FDG(P<0.05)。
- 单周期[177Lu]Lu-Evans blue-FAPI剂量为2.22 GBq,全身吸收剂量4.02E-01±3.54E-02 Gy,有效剂量4.01E+02±4.18E+01 mSv。
临床怎么用
- 作者认为[68Ga]Ga-FAPI-04可能是评估孤立性纤维性肿瘤有前景的PET显像剂。
- 作者认为该类肿瘤高表达FAP有望成为潜在治疗靶点。
- 4例高摄取患者接受单周期2.22 GBq [177Lu]Lu-Evans blue-FAPI治疗后耐受良好,随访病情稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performance of fibroblast activation protein inhibitor (FAPI), [68Ga]Ga-DOTA-FAPI-04 (denoted as [68Ga]Ga-FAPI-04), and conventional [18F]FDG PET/CT in patients with recurrent or metastatic SFTs head to head and to preliminarily explore the value of FAP-targeted radiopharmaceutical therapy with 177Lu for SFT patients. Methods: Thirty-one participants (21 men, 44 ± 13 y) with suspected recurrent or metastatic SFTs underwent both [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT within 1 wk. The positive-lesion rates of the 2 PET/CT scans in the different organs involved and the uptake values (SUVmax) were compared. Four patients with high [68Ga]Ga-FAPI-04 uptake received single-cycle therapy of 2.22 GBq of a [177Lu]Lu-labeled, FAP-targeted radiopharmaceutical, [177Lu]Lu-Evans blue-FAPI, and were followed up for 4 mo. Results: In 522 local recurrences and distant metastases in the 31 patients, [68Ga]Ga-FAPI-04 PET detected significantly more lesions than did [18F]FDG (87.0% vs. 45.4%, P < 0.001). In terms of lesion uptake values, [68Ga]Ga-FAPI-04 PET showed a mean SUVmax higher than that of [18F]FDG in most recurrence or metastatic organs (bone, lung, central nervous system, pancreas, and pleura, P < 0.001; kidney and abdominopelvic cavity, P = 0.001; muscle and pericardium, P < 0.05). Four patients tolerated [177Lu]Lu-Evans blue-FAPI well. The total-body absorbed dose and the effective dose were 4.02E-01 ± 3.54E-02 Gy and 4.01E+02 ± 4.18E+01 mSv, respectively. Subsequent follow-up with [68Ga]Ga-FAPI-04 PET showed that these patients were in stable condition. Conclusion: [68Ga]Ga-FAPI-04 may be a promising PET agent for the assessment of SFTs. Given the lack of effective treatments for advanced SFTs, high FAP expression in this type of tumor is expected to become a potential treatment target.
引用
- Wang R, Wang J, Xiang J, et al. Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 40049742. doi:10.2967/jnumed.124.268258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。